Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Prediction: Beyond Meat Stock Will Underperform for the Year Despite Its Recent 440% Rally (Fool) +++ BEYOND MEAT Aktie +6,20%

IOVANCE Aktie

 >IOVANCE Aktienkurs 
1.84 EUR    +16.5%    (Tradegate)
Ask: 1.892 EUR / 10000 Stück
Bid: 1.8648 EUR / 10000 Stück
Tagesumsatz: 138950 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
IOVANCE Aktie über LYNX handeln
>IOVANCE Performance
1 Woche: -8,5%
1 Monat: -17,7%
3 Monate: -32,6%
6 Monate: -49,7%
1 Jahr: -84,4%
laufendes Jahr: -76,7%
>IOVANCE Aktie
Name:  IOVANCE BIOTHERAPEUTICS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US4622601007 / A2DT49
Symbol/ Ticker:  2LB (Frankfurt) / IOVA (NASDAQ)
Kürzel:  FRA:2LB, ETR:2LB, 2LB:GR, NASDAQ:IOVA
Index:  -
Webseite:  https://www.iovance.com/
Profil:  Iovance Biotherapeutics, Inc. is a commercial-stag..
>Volltext..
Marktkapitalisierung:  568.71 Mio. EUR
Unternehmenswert:  358.63 Mio. EUR
Umsatz:  209.72 Mio. EUR
EBITDA:  -316.76 Mio. EUR
Nettogewinn:  -338.58 Mio. EUR
Gewinn je Aktie:  -1.07 EUR
Schulden:  46.17 Mio. EUR
Liquide Mittel:  115.03 Mio. EUR
Operativer Cashflow:  -263.46 Mio. EUR
Bargeldquote:  2.33
Umsatzwachstum:  570.12%
Gewinnwachstum:  19.46%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  IOVANCE
Letzte Datenerhebung:  06.11.25
>IOVANCE Kennzahlen
Aktien/ Unternehmen:
Aktien: 361.85 Mio. St.
Frei handelbar: 80.88%
Rückkaufquote: -32.69%
Mitarbeiter: 838
Umsatz/Mitarb.: 0.17 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 331.26%
Bewertung:
KGV: -
KGV lG: -
KUV: 2.7
KBV: 0.92
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 10.81%
Gewinnmarge: -161.44%
Operative Marge: -170.02%
Managementeffizenz:
Gesamtkaprendite: -41.66%
Eigenkaprendite: -53.16%
>IOVANCE Peer Group

Es sind 597 Aktien bekannt.
 
06.11.25 - 14:06
 Iovance Biotherapeutics reports mixed Q3 results; reaffirms FY25 outlook (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
17.10.25 - 23:18
 Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN)
 
SAN CARLOS, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on October 16, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 62,790 shares of Iovance's common stock to nine new, non-executive employees....
17.10.25 - 13:01
 Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health (Fool)
 
Is there a glimmer of hope for either of these underperforming healthcare companies?...
13.10.25 - 12:24
 Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire? (Fool)
 
Investors have certainly seen explosive gains from shares of biopharma companies in similar situations....
19.09.25 - 23:03
 Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN)
 
SAN CARLOS, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on September 18, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 22,810 shares of Iovance's common stock to two new, non-executive employees....
29.08.25 - 14:33
 Iovance Biotherapeutics to Present at Upcoming Conferences (GlobeNewswire EN)
 
SAN CARLOS, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences:...
26.08.25 - 16:30
 IOVA Stock Drops 6% on $350M Common Stock Offering (Zacks)
 
Iovance shares slid 6% after unveiling a $350 million stock offering, raising dilution concerns while funding growth plans for Amtagvi and its pipeline....
25.08.25 - 23:48
 Why Iovance Biotherapeutics Stock Got Mashed on Monday (Fool)
 
The company announced a flotation of its common shares that is potentially quite dilutive....
22.08.25 - 23:18
 Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN)
 
SAN CARLOS, Calif., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on August 21, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 182,370 shares of Iovance's common stock to 20 new, non-executive employees....
19.08.25 - 21:48
 Why Iovance Biotherapeutics Stock Was Climbing Today (Fool)
 
One and a half years after getting the nod from the U.S. Food and Drug Administration, its Amtagvi moves forward in a neighboring country....
18.08.25 - 23:06
 Iovance gets conditional Health Canada approval for Amtagvi (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
18.08.25 - 22:18
 Iovance′s Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma (GlobeNewswire EN)
 
First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy...
12.08.25 - 23:33
 Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight (PR Newswire)
 
Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics, Biosyngen, KSQ Therapeutics, and others, are currently engaged in the development and production of......
09.08.25 - 02:24
 Why Iovance Biotherapeutics Stock Plummeted Today (Fool)
 
The company's top line nearly doubled....
08.08.25 - 21:54
 Iovance falls after missing Q2 expectation (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
08.08.25 - 20:30
 IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi (Zacks)
 
Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy....
08.08.25 - 09:21
 Iovance outlines $250M–$300M 2025 revenue target as restructuring aims to boost margins and expand Amtagvi adoption (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
07.08.25 - 23:24
 Iovance (IOVA) Q2 Revenue Jumps 93% (Fool)
 
Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Die Dahingegangenen bleiben mit dem Wesentlichen, womit sie auf uns gewirkt haben, mit uns lebendig, solange wir leben. - Hermann Hesse
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!